RDHL — Redhill Biopharma Share Price
0.000.00%
Last trade - 00:00- $7.15m
- $2.75m
- $6.53m
- 40
- 91
- 16
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.48 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.1 | ||
| EV to EBITDA | 0.08 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 872.98% | ||
| Return on Equity | n/a | ||
| Operating Margin | 508.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.29 | 64.36 | 85.76 | 61.8 | 6.53 | 20.8 | 38 | -4.82% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Directors
- Dror Ben-Asher CHM (56)
- Micha Ben Chorin CFO (52)
- Einav Nagar-Brenner FID
- Gilead Raday COO (47)
- Rob Jackson SVP
- Patricia Anderson SVP
- Reza Fathi SVP (67)
- Robert Gilkin SVP
- David Wasserman SVP
- June Almenoff CSO (65)
- Todd Krzyzaniak VFN
- Michelle Snelling VPR
- Danielle Abramson VPR
- Aida Bibliowicz VPR
- Ben Martie VPR
- Shani Maurice VPR
- Craig Miller VPR
- Steven Thomasian VPR
- Reginald Williams VPR
- Rick Scruggs OTH (61)
- Adi Frish OTH (51)
- Guy Goldberg OTH (45)
- Shmuel Cabilly IND (71)
- Alessandro Della Cha IND (58)
- Alla Felder IND (48)
- Kenneth Reed IND (67)
- Eric Swenden IND (77)
- Ofer Tsimchi IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 3rd, 2009
- Public Since
- February 1st, 2011
- No. of Shareholders
- 4
- No. of Employees
- 53
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 7,869,853,000
- Address
- 21 Ha'arba'a St., TEL AVIV-YAFO, 6473921
- Web
- https://www.redhillbio.com/
- Phone
- +972 35413131
- Contact
- Alexandra Okmian
- Auditors
- Kesselman & Kesselman
Upcoming Events for RDHL
Q2 2024 Redhill Biopharma Ltd Earnings Release
Similar to RDHL
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the Redhill Biopharma share price?
As of Today at 22:54 UTC, shares in Redhill Biopharma are trading at $0.37. This share price information is delayed by 15 minutes.
How has the Redhill Biopharma share price performed this year?
Shares in Redhill Biopharma last closed at $0.37 and the price had moved by -78.58% over the past 365 days. In terms of relative price strength the Redhill Biopharma share price has underperformed the S&P500 Index by -82.95% over the past year.
What are the analyst and broker recommendations for Redhill Biopharma?
The overall consensus recommendation for Redhill Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Redhill Biopharma dividend yield?
Redhill Biopharma does not currently pay a dividend.
Does Redhill Biopharma pay a dividend?
Redhill Biopharma does not currently pay a dividend.
When does Redhill Biopharma next pay dividends?
Redhill Biopharma does not currently pay a dividend.
How do I buy Redhill Biopharma shares?
To buy shares in Redhill Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Redhill Biopharma?
As of the previous close price of $0.37, shares in Redhill Biopharma had a market capitalisation of $7.21m.
Where are Redhill Biopharma shares listed?
Here are the trading details for Redhill Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: RDHL
What kind of share is Redhill Biopharma?
Based on an overall assessment of its quality, value and momentum Redhill Biopharma is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Redhill Biopharma share price forecast for 2024?
The analyst consensus target price for shares in Redhill Biopharma is $760.00. That is 207380.21% above the last closing price of $0.37.
Analysts covering Redhill Biopharma currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
What is the trend in the Redhill Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Redhill Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -78.23%.
As of the last closing price of $0.37, shares in Redhill Biopharma were trading -45.61% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Redhill Biopharma PE Ratio?
The Redhill Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Redhill Biopharma?
Redhill Biopharma's management team is headed by:
- Dror Ben-Asher - CHM
- Micha Ben Chorin - CFO
- Einav Nagar-Brenner - FID
- Gilead Raday - COO
- Rob Jackson - SVP
- Patricia Anderson - SVP
- Reza Fathi - SVP
- Robert Gilkin - SVP
- David Wasserman - SVP
- June Almenoff - CSO
- Todd Krzyzaniak - VFN
- Michelle Snelling - VPR
- Danielle Abramson - VPR
- Aida Bibliowicz - VPR
- Ben Martie - VPR
- Shani Maurice - VPR
- Craig Miller - VPR
- Steven Thomasian - VPR
- Reginald Williams - VPR
- Rick Scruggs - OTH
- Adi Frish - OTH
- Guy Goldberg - OTH
- Shmuel Cabilly - IND
- Alessandro Della Cha - IND
- Alla Felder - IND
- Kenneth Reed - IND
- Eric Swenden - IND
- Ofer Tsimchi - IND